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Summary
Primary coenzyme Q  (CoQ ) deficiency is usually associated with
multisystem involvement, including neurologic manifestations such as fatal neonatal
encephalopathy with hypotonia; a late-onset slowly progressive multiple-system atrophy-like
phenotype (neurodegeneration with autonomic failure and various combinations of parkinsonism
and cerebellar ataxia, and pyramidal dysfunction); and dystonia, spasticity, seizures, and
intellectual disability. Steroid-resistant nephrotic syndrome (SRNS), the hallmark renal
manifestation, is often the initial manifestation either as isolated renal involvement that
progresses to end-stage renal disease (ESRD), or associated with encephalopathy (seizures,
stroke-like episodes, severe neurologic impairment) resulting in early death. Hypertrophic
cardiomyopathy (HCM), retinopathy or optic atrophy, and sensorineural hearing loss can also be
seen.
The diagnosis of primary CoQ  deficiency in a proband is established by
identification of biallelic pathogenic variants in one of the nine genes encoding proteins directly
involved in the synthesis of coenzyme Q  or by detection of reduced levels of CoQ
(ubiquinone) in skeletal muscle or reduced activities of complex I+III and II+III of the
mitochondrial respiratory chain on frozen muscle homogenates.
Treatment of manifestations: In individuals with primary CoQ  deficiency early
treatment with high-dose oral CoQ  supplementation (ranging from 5 to 50 mg/kg/day) can limit
disease progression and reverse some manifestations; however, established severe neurologic
and/or renal damage cannot be reversed. ACE inhibitors may be used in combination with CoQ
supplementation in persons with proteinuria; renal transplantation is an option for those with
ESRD. Treatment of hypertrophic cardiomyopathy, retinopathy, and sensorineural hearing loss is
per usual practice.
Prevention of primary manifestations: Supplementation with high-dose oral CoQ  can prevent
progression of the renal disease and onset of neurologic manifestations.
Surveillance: Periodic neurologic evaluation, urine analysis (for proteinuria) and renal function
tests, ophthalmologic evaluation, and audiometry.
Evaluation of relatives at risk: Presymptomatic diagnosis for the purpose of early treatment with
CoQ  supplementation is warranted for relatives at risk.
Primary coenzyme Q  deficiency is inherited in an autosomal recessive
manner. At conception, each sib of an affected individual has a 25% chance of being affected, a
50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a
carrier. Carrier testing for at-risk relatives, prenatal testing for pregnancies at increased risk, and
preimplantation genetic diagnosis are possible if the pathogenic variants in a family are known.
Diagnosis
Primary deficiency of coenzyme Q , a lipid component of the mitochondrial respiratory chain, is
10
10
Author Information
10 10
10
10 10
10
10
10
10
10
10
10
Primary Coenzyme Q10 Deficiency - GeneReviews® - NCBI B... https://www.ncbi.nlm.nih.gov/books/NBK410087/
1 di 29 15/03/17, 17:31
classified as a mitochondrial respiratory chain disorder [DiMauro et al 2013].
For this GeneReview the term ‘primary coenzyme Q  deficiency’ refers to the group of
conditions characterized by a reduction of coenzyme Q  (CoQ ) levels in tissues or cultured
cells associated with mutation of the nine genes involved in the biosynthesis of coenzyme Q
(collectively called ‘COQ genes’).
There are no formal diagnostic criteria for primary coenzyme Q  deficiency.
Suggestive Findings
Primary coenzyme Q  deficiency, which is associated with an extremely heterogeneous group of
clinical manifestations, should be suspected in individuals with the following clinical findings
(Table 1).
Clinical findings
Steroid-resistant nephrotic syndrome (SRNS) without mutation of NPHS1 (encoding
nephrin) or NPHS2 (encoding podocin), especially when accompanied by deafness,
retinopathy, and/or other CNS manifestations [Emma et al 2012, Desbats et al 2015a]
Clinical features of a mitochondrial encephalomyopathy, including neurologic findings
(hypotonia, seizures, dystonia, nystagmus, cerebellar ataxia or pyramidal dysfunction,
spasticity, peripheral neuropathy, and intellectual disability), myopathy, retinopathy, or
optic atrophy, sensorineural hearing loss, and/or hypertrophic cardiomyopathy (Table 1).
Unexplained ataxia (especially if family history suggests autosomal recessive inheritance)
[Rahman et al 2012]
Subacute exercise intolerance (with onset usually between ages 6 and 33 years) with
proximal muscle weakness and elevated CK (≤20 times upper limit of the control range)
[Rahman et al 2012]
Table 1.
Clinical Manifestations Associated with Mutation of Genes Encoding Proteins Directly Involved
in the Synthesis of Coenzyme Q
Gene
Clinical Manifestations
Renal Heart Eye Hearing Neurologic Muscle
COQ2 SRNS HCM Retinopathy SNHL
Encephalopathy 
Seizures
Other 
Myopathy
COQ4
Heart
failure
HCM
Encephalopathy
Seizures
Other 
Myopathy
COQ6 SRNS SNHL
Encephalopathy
Seizures
COQ7
Encephalopathy
ID
Peripheral
neuropathy
Muscle
weakness
COQ8A
Encephalopathy
Cerebellar ataxia
Dystonia
Spasticity
Exercise
intolerance
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1.
2.
3.
4.
Gene
Clinical Manifestations
Renal Heart Eye Hearing Neurologic Muscle
Seizures
COQ8B SRNS ID
COQ9 Tubulopathy HCM Encephalopathy Myopathy
PDSS1
Optic
atrophy
Encephalopathy
Peripheral
neuropathy
PDSS2 SRNS Retinopathy SNHL
Leigh syndrome
Ataxia
Table contents are ordered by gene.
HCM = hypertrophic cardiomyopathy
ID = intellectual disability
SNHL = sensorineural hearing loss
SRNS = steroid-resistant nephrotic syndrome
Encephalopathy comprises a wide spectrum of brain involvement with different clinical and neuroradiologic
features, often not further explicated by the reporting authors.
Adult-onset multisystem atrophy-like phenotype [Desbats et al 2016]
Severe hypotonia, respiratory insufficiency, cerebellar hypoplasia, slowly progressive neurologic deterioration
Because individuals with COQ6- and COQ8B- related coenzyme Q  deficiency were ascertained by the
presence of SRNS, the authors cannot exclude the possibility that biallelic pathogenic variants in these two
genes could also cause a broader phenotype.
Laboratory findings. Serum or plasma lactate concentration may be high in those individuals
with severe neonatal onset. Of note, normal lactate levels do not exclude the possibility of
coenzyme Q  deficiency [Rahman et al 2012].
CSF lactate concentration may be more sensitive than serum/plasma levels, but can be normal.
Establishing the Diagnosis
The diagnosis of primary coenzyme Q  deficiency in a proband is established by identification
of biallelic pathogenic variants in one of the nine genes encoding proteins directly involved in the
synthesis of coenzyme Q  (Table 2).
Note: If a diagnosis of primary coenzyme Q  deficiency cannot be established by molecular
genetic testing, biochemical testing may be considered.
Molecular Genetic Testing
Molecular testing approaches can include single-gene testing, use of a multi-gene panel, and
more comprehensive genomic testing.
Serial single gene testing based on clinical findings (see Table 1). Sequence analysis is
performed first, followed by deletion/duplication analysis if only one or no pathogenic
variant is identified.
Use of a multi-gene panel that includes the nine genes in Table 2 and some or all of the
other genes of interest; for example, genes:
Known (or suspected) to be required for CoQ  biosynthesis but not identified to
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date as a cause of primary CoQ  deficiency (i.e., ADCK1, ADCK2, ADCK5, COQ3,
COQ10a, COQ10b, FDXR, and FDX2 (FDX1L) [Desbats et al 2015a])
Associated with secondary deficiencies of coenzyme Q  (APTX, BRAF, ETFDH)
(see Differential Diagnosis)
Associated with a specific phenotype (e.g., steroid-resistant nephrotic syndrome,
ataxia)
Note: (1) The choice of the specific panel depends on the phenotype observed in the
patient. (2)The genes included in the panel and the diagnostic sensitivity of the testing used
for each gene vary by laboratory and over time.
More comprehensive genomic testing. Because of the large (and still growing) number of
genes involved, the rarity of primary coenzyme Q  deficiency, the incomplete knowledge
of the coenzyme Q  biosynthetic pathway, and the continuous reduction in the cost of
genomic testing, exome sequencing is an alternative to the use of single-gene testing and
specific multi-gene panels [Desbats et al 2015a, Desbats et al 2015b]. In fact, exome
sequencing may also be able to detect all possible genetic causes of both primary and
secondary coenzyme Q  deficiency (see Differential Diagnosis). For more information on
comprehensive genome sequencing click here.
Table 2.
Summary of Molecular Genetic Testing Used in Primary Coenzyme Q  Deficiency
Gene 
Number of Families
w/Coenzyme Q  Deficiency
Attributed to Mutation of This
Gene
Proportion of Pathogenic Variants 
Detected by Test Method
Sequence
analysis 
Gene-targeted
deletion/duplication
analysis
COQ2 10 
All pathogenic
variants reported
to date
Unknown
COQ4 9 
All pathogenic
variants reported
to date
Unknown 
COQ6 5 
All pathogenic
variants reported
to date
Unknown
COQ7 1 
All pathogenic
variants reported
to date
Unknown
COQ8A 14 
All pathogenic
variants reported
to date
Unknown 
COQ8B 34 
Most pathogenic
variants reported
to date
Unknown
COQ9 2 
All pathogenic
variants reported
to date
Unknown
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1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Gene 
Number of Families
w/Coenzyme Q  Deficiency
Attributed to Mutation of This
Gene
Proportion of Pathogenic Variants  Detected
by Test Method
Sequence
analysis 
Gene-targeted
deletion/duplication
analysis
PDSS1 2 
All pathogenic
variants reported
to date
Unknown
PDSS2 2 
All pathogenic
variants reported
to date
Unknown
Unknown NA NA
See Table A. Genes and Databases for chromosome locus and protein.
See Molecular Genetics for information on allelic variants detected in this gene.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or
pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and
splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider
in interpretation of sequence analysis results, click here.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be
used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA),
and a gene-targeted microarray designed to detect single-exon deletions or duplications.
Quinzii et al [2006], Diomedi-Camassei et al [2007], Mollet et al [2007], Dinwiddie et al [2013], Jakobs et al
[2013], McCarthy et al [2013], Mitsui et al [2013], Scalais et al [2013], Desbats et al [2015b], Desbats et al
[2016]
Salviati et al [2012], Brea-Calvo et al [2015], Chung et al [2015]
To date only one individual has had a heterozygous deletion encompassing COQ4 [Salviati et al 2012].
Heeringa et al [2011], Doimo et al [2014]
Freyer et al [2015]
Lagier-Tourenne et al [2008], Mollet et al [2008], Anheim et al [2010], Gerards et al [2010], Horvath et al
[2012], Terracciano et al [2012], Mignot et al [2013], Blumkin et al [2014], Liu et al [2014]
A deletion from exon 3 to exon 15 has been described [Lagier-Tourenne et al 2008]
Ashraf et al [2013], Korkmaz et al [2016]
Duncan et al [2009], Rahman et al [2012], Danhauser et al [2016]
Mollet et al [2007], Vasta et al [2012]
Rötig et al [2000], Rahman et al [2012]
To date many individuals with reduced CoQ  in cells or tissues lack a clear genetic diagnosis, making it
impossible to distinguish between primary and secondary CoQ  deficiency [Trevisson et al 2011].
Biochemical Testing
The following findings on biochemical testing can differentiate coenzyme Q  deficiency from
other mitochondrial disorders with similar clinical findings, but cannot differentiate primary from
secondary coenzyme Q  deficiency (see Differential Diagnosis).
Reduced levels of CoQ  in skeletal muscle [Montero et al 2008]. Note: While coenzyme
Q  measurements may be performed on cultured skin fibroblasts or blood mononuclear
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cells, these tissues may not be reliable in detecting secondary coenzyme Q  defects
[Yubero et al 2015].
Reduced activities of complex I+III and II+III of the mitochondrial respiratory chain on
frozen muscle homogenates. These enzymatic activities, which depend on endogenous
coenzyme Q  are reduced in persons with a defect in CoQ  even when isolated complex
II and III respiratory chain activities are normal [Rahman et al 2012].
Clinical Characteristics
Clinical Description
The manifestations of primary coenzyme Q  deficiency vary (Table 1). Traditionally, clinical
presentations have been classified into five distinct phenotypes: encephalomyopathy, cerebellar
ataxia, severe infantile multisystem disease, steroid-resistant nephrotic syndrome, and isolated
myopathy [Emmanuele et al 2012]. This classification is probably now outdated because the
range of clinical phenotypes is much wider, and different combinations of findings with
significant overlap have been identified. Furthermore, no individuals with molecularly confirmed
primary CoQ  deficiency with isolated myopathy have been reported [Authors, personal
observation], since most individuals reported with predominantly muscle disease have secondary
coenzyme Q  deficiency [Doimo et al 2014] (see Differential Diagnosis).
The broad age of onset of primary coenzyme Q  deficiency is exemplified by COQ2-related
coenzyme Q  deficiency, in which onset ranges from birth to the seventh decade.
The principal clinical manifestations of primary CoQ  deficiency (regardless of genetic cause)
are summarized below [Desbats et al 2015a], and followed by a summary of the phenotypes of
COQ2-, COQ8A-, and COQ8B-related CoQ  deficiencies, the three most common causes of
primary coenzyme Q  deficiency.
Principal Clinical Manifestations
Neurologic. Central nervous system (CNS) manifestations include encephalopathy (a wide
spectrum of brain involvement with different clinical and neuroradiologic features often not
further specified). In some individuals encephalopathy is associated with findings on
neuroimaging resembling Leigh syndrome [López et al 2006] or MELAS (with stroke-like
episodes) [Salviati et al 2005]. CNS manifestations often include seizures, dystonia, spasticity,
and/or intellectual disability [López et al 2006, Mollet et al 2007, Heeringa et al 2011].
The age of onset and clinical severity range from fatal neonatal encephalopathy with hypotonia
[Mollet et al 2007, Jakobs et al 2013] to a late-onset slowly progressive multiple-system atrophy
(MSA)-like phenotype, a neurodegenerative disorder characterized by autonomic failure
associated with various combinations of parkinsonism, cerebellar ataxia, and pyramidal
dysfunction. This clinical picture resembling MSA with onset in the seventh decade was reported
in two multiplex families with COQ2-related coenzyme Q  deficiency [Mitsui et al 2013].
Individuals with COQ8A-related coenzyme Q  deficiency display progressive cerebellar atrophy
and ataxia with intellectual disability and seizures [Lagier-Tourenne et al 2008, Mollet et al
2008].
Peripheral neuropathy with absent deep tendon reflexes has been reported in the two sibs with
PDSS1-related coenzyme Q  deficiency; the age at onset and frequency of this manifestation are
not known.
Given the small number of affected individuals described to date, clinical data are insufficient to
make any generalizations about other neurologic manifestations (e.g., dystonia, spasticity,
seizures, intellectual disability).
Renal. Steroid-resistant nephrotic syndrome (SRNS), an unusual feature of mitochondrial
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disorders, is a hallmark of primary CoQ  deficiency. If not treated with coenzyme Q  (see
Management), SRNS usually progresses to end-stage renal disease (ESRD).
Renal involvement usually manifests as proteinuria in infancy. Affected individuals often present
initially with SRNS that leads to ESRD, followed by an encephalomyopathy with seizures and
stroke-like episodes resulting in severe neurologic impairment and ultimately death [Rötig et al
2000, Salviati et al 2005, Heeringa et al 2011].
Some affected individuals manifest only SRNS with onset in the first or second decade of life and
slow progression to ESRD without extrarenal manifestations.
One of the two individuals in a family with COQ9-related coenzyme Q  deficiency manifested
tubulopathy within a few hours after birth.
Cardiac. Hypertrophic cardiomyopathy (HCM) has been reported in:
Neonatal-onset COQ2-related coenzyme Q  deficiency [Scalais et al 2013];
COQ4-related coenzyme Q  deficiency manifesting as prenatal-onset HCM [Brea-Calvo
et al 2015];
COQ9-related coenzyme Q  deficiency manifesting as neonatal-onset lactic acidosis
followed by a multisystem disease that included HCM [Duncan et al 2009]. The cardiac
disease worsened despite treatment with CoQ
Ocular. Retinopathy is observed in some persons with COQ2-related coenzyme Q  deficiency
[Desbats et al 2016].
Optic atrophy is present in some individuals with PDSS1-related coenzyme Q  deficiency
[Mollet et al 2007] and PDSS2-related coenzyme Q  deficiency [Rötig et al 2000, Rahman et al
2012]. Data regarding age of onset and course of the eye manifestations are not available.
Hearing. Sensorineural hearing loss, which is common in individuals with COQ6-related
coenzyme Q  deficiency, is also observed in some individuals with COQ2-related coenzyme Q
deficiency [Author, personal observation].
Muscle findings include weakness and exercise intolerance. Muscle biopsy may show
nonspecific signs of lipid accumulation and mitochondrial proliferation [Trevisson et al 2011,
Desbats et al 2015b].
Prognosis. Data on the prognosis of primary CoQ  deficiency are limited due to the small
number of affected individuals reported to date. It is a progressive disorder, with variable rates of
progression and tissue involvement depending on the gene that is mutated and the severity of the
CoQ  deficiency.
Children with severe multisystem CoQ  deficiency generally die within the neonatal period or in
the first year of life.
The only child reported with COQ9-related coenzyme Q  deficiency died before age two years
of a progressive multisystem disorder [Duncan et al 2009].
Of note, supplementation with high-dose oral CoQ  can change the natural history of the disease
by blocking progression of the renal disease and preventing the onset of neurologic
manifestations in persons with biallelic pathogenic variants in COQ2, COQ6, COQ8B, and
PDSS2 [Montini et al 2008; Author, personal communication].
Phenotypes of COQ2-, COQ8A-, and COQ8B-Related Coenzyme Q  Deficiency
COQ2. The findings in affected individuals from the ten families described to date differ in
severity and age of onset [Mollet et al 2007, Diomedi-Camassei et al 2007, Dinwiddie et al 2013,
Jakobs et al 2013, McCarthy et al 2013, Mitsui et al 2013, Scalais et al 2013, Desbats et al 2015b,
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Desbats et al 2016].
The main clinical features include SRNS, which can be:
Isolated [Salviati et al 2005, Diomedi-Camassei et al 2007, McCarthy et al 2013];
Associated with encephalomyopathy [Salviati et al 2005] or severe multiple-system disease
[Diomedi-Camassei et al 2007, Mollet et al 2007, Jakobs et al 2013];
Associated with late-onset multiple-system atrophy with retinitis pigmentosa [Mitsui et al
2013, Desbats et al 2016].
COQ8A. Affected individuals experience onset of muscle weakness and reduced exercise
tolerance between ages 18 months and three years, followed by cerebellar ataxia (the
predominant clinical feature) with severe cerebellar atrophy on MRI. The disease course varies,
including both progressive and apparently self-limited ataxia. The ataxia may be:
Isolated [Lagier-Tourenne et al 2008];
Progressive with cerebellar atrophy in addition to intellectual disability, epilepsy,
stroke-like episodes, and/or exercise intolerance [Auré et al 2004, Lagier-Tourenne et al
2008, Mollet et al 2008, Terracciano et al 2012].
COQ8B. Affected individuals generally manifest SRNS in the second decade, and frequently
evolve to end-stage kidney disease [Ashraf et al 2013, Korkmaz et al 2016]. In addition, four
affected individuals were reported with mild intellectual disability, two with occasional seizures,
and one with retinitis pigmentosa.
Genotype-Phenotype Correlations
To date the limited number of affected individuals reported for each related gene complicates the
delineation of genotype-phenotype correlations.
The factors that determine the clinical variability observed in primary CoQ  deficiency are
unknown. One possibility is that the residual activity of the mutated protein modulates the
phenotype; however, experimental data to evaluate this hypothesis are lacking.
Prevalence
The estimated overall incidence of primary coenzyme Q  deficiency is less than 1:100,000; no
precise epidemiologic data are available [Desbats et al 2015a].
Genetically Related (Allelic) Disorders
No phenotypes other than those discussed in this GeneReview are known to be associated with
mutation of COQ2, COQ4, COQ7, COQ8A, COQ8B, COQ9, PDSS1, or PDSS2.
COQ6. Heterozygous germline pathogenic variants in COQ6 have been associated with
susceptibility to schwannomatosis, a finding that has been disputed [Trevisson et al 2015].
Differential Diagnosis
Note: It is important to consider primary CoQ  deficiency in individuals with the following
diverse presentations because primary CoQ  deficiency is potentially treatable.
Mitochondrial encephalomyopathies. See Mitochondrial Disorders Overview. The clinical
manifestations of mitochondrial encephalomyopathies and primary coenzyme Q  deficiency can
often be indistinguishable, especially in the severe phenotypes.
Steroid-resistant nephrotic syndrome (SRNS) that results from mutation of other genes
important for podocyte function (including DGKE, LAMB2, NPHS1, NPHS2, PLCE1, PTPRO,
and WT1) is clinically indistinguishable from the SRNS resulting from primary CoQ  deficiency.
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Early onset ataxia. See Hereditary Ataxia Overview.
Muscle disease/myopathy. See Limb-Girdle Muscular Dystrophy Overview and Congenital
Muscular Dystrophy Overview.
Secondary coenzymeQ  deficiencies are those disorders in which reduction in CoQ  levels is
caused by mutation of genes not directly related to coenzyme Q  biosynthesis [Trevisson et al
2011]. Molecular genetic testing is the only way to distinguish primary coenzyme Q  deficiency
from secondary coenzyme Q  deficiencies.
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with primary coenzyme
Q  deficiency, the following evaluations are recommended:
Neurologic evaluation including brain MRI
Renal evaluation with particular attention to the presence of proteinuria
Cardiac evaluation including echocardiography with particular attention to possible
hypertrophic cardiomyopathy
Ophthalmologic evaluation with particular attention to possible retinopathy and optic
atrophy
Audiometry with particular attention to possible sensorineural hearing loss
Consultation with a clinical geneticist and/or genetic counselor
Treatment of Manifestations
Pharmacologic Treatment
Coenzyme Q  supplementation. Individuals with primary CoQ  deficiency may respond well
to high-dose oral CoQ  supplementation (ranging from 5 to 50 mg/kg/day). Soluble
formulations are apparently more bioavailable [Desbats et al 2015a].
Treatment should be instituted as early as possible [Montini et al 2008] because it can limit
disease progression and reverse some manifestations; however, established severe neurologic
and/or renal damage cannot be reversed.
Individuals with the following genetic causes of primary CoQ  deficiency apparently respond
well to CoQ  supplementation:
COQ4-related coenzyme Q  deficiency. Neurologic signs responded to CoQ
supplementation in a single individual reported to date with a heterozygous deletion
encompassing COQ4 [Salviati et al 2012]; no response was observed in patients reported
by Chung et al [2015].
COQ6-related coenzyme Q  deficiency. Homozygotes for the pathogenic variants
p.Gly255Arg or p.Ala353Asp responded [Heeringa et al 2011].
COQ8B-related coenzyme Q  deficiency. In a patient homozygous for a truncating
pathogenic variant, edema resolved and proteinuria was significantly improved.
PDSS2-related coenzyme Q  deficiency. The only kindred reported responded [Rötig et al
2000].
Data for response to CoQ  supplementation in individuals with mutation of other genes causing
primary coenzyme Q  deficiency are limited or lacking:
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COQ8A-related coenzyme Q  deficiency. While most affected individuals respond poorly
to CoQ  supplementation, three individuals had a favorable response: one had objective
stabilization of ataxia [Lagier-Tourenne et al 2008]; one had a dramatic and long-lasting
improvement of dystonia and myoclonus after six months of treatment; and in one tremor
and drawing ability improved [Mignot et al 2013].
COQ9-related coenzyme Q  deficiency. One patient with multiple-system disease
characterized by intractable seizures, global developmental delay, hypertrophic
cardiomyopathy, and renal tubular dysfunction did not respond to CoQ  supplementation;
however, this may be due to late diagnosis [Duncan et al 2009].
Ineffective treatments (or those without validated effects) for individuals with primary coenzyme
Q  deficiency include the following CoQ  derivatives:
Ubiquinol, the reduced form of CoQ  has recently become commercially available;
however, data on the therapeutic dosage and its efficacy are still lacking.
Short chain quinone analogs such as idebenone [Rötig et al 2000, López et al 2010] have
been reported to cause clinical deterioration in individuals with CoQ  deficiency
[Hargreaves 2014].
Renal Disease
ACE inhibitors may be used in combination with CoQ  supplementation in individuals with
proteinuria [Heeringa et al 2011].
Renal transplantation is an option for those with end-stage renal disease [Salviati et al 2005].
Other
Treatment of hypertrophic cardiomyopathy, retinopathy, and sensorineural hearing loss is routine
(see Hypertrophic Cardiomyopathy and Hereditary Hearing Loss and Deafness).
Prevention of Primary Manifestations
Early CoQ  supplementation may prevent the onset of manifestations of primary CoQ
deficiency (see Treatment of Manifestations).
Surveillance
While surveillance depends on the specific genetic defect and on the clinical manifestations (see
Table 1), it should always include periodic evaluations of the following: neurologic findings,
urine analysis (for proteinuria) and renal function, ophthalmologic findings, and hearing.
Note: Because cardiomyopathy to date has been found only in the most severe phenotype (i.e.,
neonatal onset), cardiac evaluation should be performed at the time of diagnosis, but not
periodically unless cardiac involvement has been documented.
Evaluation of Relatives at Risk
Given the importance of early CoQ  supplementation, it is appropriate to evaluate the sibs of a
proband who has primary coenzyme Q  deficiency in order to identify as early as possible those
sibs who would benefit from early initiation of treatment.
If the pathogenic variants in the family are known, molecular genetic testing can be used to
clarify the genetic status of at-risk sibs.
If the pathogenic variants in the family are not known and the diagnosis has been
established by biochemical findings, one can consider measuring CoQ  levels in skin
fibroblasts of at-risk sibs [Desbats et al 2015b].
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See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling
purposes.
Therapies Under Investigation
Search ClinicalTrials.gov for access to information on clinical studies for a wide range of
diseases and conditions. Note: There may not be clinical trials for this disorder.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the
nature, inheritance, and implications of genetic disorders to help them make informed medical
and personal decisions. The following section deals with genetic risk assessment and the use of
family history and genetic testing to clarify genetic status for family members. This section is not
meant to address all personal, cultural, or ethical issues that individuals may face or to substitute
for consultation with a genetics professional. —ED.
Mode of Inheritance
Primary coenzyme Q  deficiency is generally inherited in an autosomal recessive manner.
Primary coenzyme Q  deficiency associated with a de novo contiguous gene deletion
encompassing COQ4 was reported in one individual [Salviati et al 2012].
Risk to Family Members – Autosomal Recessive Inheritance
Parents of a proband
The parents of an individual with a confirmed molecular genetic diagnosis of primary
coenzyme Q  deficiency are obligate heterozygotes (i.e., carriers of a pathogenic variant
in COQ2, COQ4, COQ6, COQ7, COQ8A, COQ8B, COQ9, PDSS1, or PDSS2).
Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.
Sibs of a proband
At conception, each sib of an affected individual has a 25% chance of being affected, a
50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and
not a carrier.
Heterozygotes are asymptomatic and are not at risk of developing the disorder.
Offspring of a proband. The offspring of an individual with a confirmed molecular genetic
diagnosis of primary coenzyme Q  deficiency are obligate heterozygotes (i.e., carriers of a
pathogenic variant in COQ2, COQ4, COQ6, COQ7, COQ8A, COQ8B, COQ9, PDSS1, or
PDSS2).
Other family members. Each sib of the parents of a proband with a confirmed molecular genetic
diagnosis of primary coenzyme Q  deficiency is at a 50% risk of being a carrier of a pathogenic
variant.
Heterozygote (Carrier) Detection
Carrier testing for at-risk relatives requires prior identification of the COQ2, COQ4, COQ6,
COQ7, COQ8A, COQ8B, COQ9, PDSS1, or PDSS2 pathogenic variants in the family.
Related Genetic Counseling Issues
See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives
for the purpose of early diagnosis and treatment.
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Family planning
The optimal time for determination of genetic risk, clarification of carrier status, and
discussion of the availability of prenatal testing is before pregnancy.
It is appropriate to offer genetic counseling (including discussion of potential risks to
offspring and reproductive options) to young adults who are affected, are carriers, or are at
risk of being carriers.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible
future use. Because it is likely that testing methodology and our understanding of genes, allelic
variants, and diseases will improve in the future, consideration should be given to banking DNA
of affected individuals.
Prenatal Testing and Preimplantation Genetic Diagnosis
Once the COQ2, COQ4, COQ6, COQ7, COQ8A, COQ8B, COQ9, PDSS1, or PDSS2 pathogenic
variants have been identified in an affected family member, prenatal testing for a pregnancy at
increased risk and preimplantation genetic diagnosis for primary coenzyme Q  deficiency are
possible.
Differences in perspective may exist among medical professionals and within families regarding
the use of prenatal testing, particularly if the testing is being considered for the purpose of
pregnancy termination rather than early diagnosis. Although most centers would consider
decisions about prenatal testing to be the choice of the parents, discussion of these issues is
appropriate.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support
organizations and/or registries for the benefit of individuals with this disorder and their families.
GeneReviews is not responsible for the information provided by other organizations. For
information on selection criteria, click here.
Medline Plus
Coenzyme Q-10
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the
GeneReview: tables may contain more recent information. —ED.
Table A.
Primary Coenzyme Q10 Deficiency: Genes and Databases
Gene Chromosome
Locus
Protein Locus
Specific
HGMD
COQ2 4q21.22-q21.23 Para-hydroxybenzoate--
polyprenyltransferase, mitochondrial
COQ2
database
COQ2
COQ4 9q34.11 Ubiquinone biosynthesis protein COQ4
homolog, mitochondrial
COQ4
COQ6 14q24.3 Ubiquinone biosynthesis monooxygenase
COQ6, mitochondrial
COQ6
COQ7 16p12.3 5-demethoxyubiquinone hydroxylase,
mitochondrial
COQ7
10
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COQ8A 1q42.13 Atypical kinase ADCK3, mitochondrial ADCK3
database
COQ8A
COQ8B 19q13.2 Atypical kinase COQ8B, mitochondrial COQ8B
COQ9 16q21 Ubiquinone biosynthesis protein COQ9,
mitochondrial
COQ9
database
COQ9
PDSS1 10p12.1 Decaprenyl-diphosphate synthase subunit 1 PDSS1
database
PDSS1
PDSS2 6q21 Decaprenyl-diphosphate synthase subunit 2 PDSS2
database
PDSS2
Data are compiled from the following standard references: gene from HGNC; chromosome locus, locus name,
critical region, complementation group from OMIM; protein from UniProt. For a description of databases (Locus
Specific, HGMD) to which links are provided, click here.
Table B.
OMIM Entries for Primary Coenzyme Q10 Deficiency (View All in OMIM)
601683 COQ7, S. CEREVISIAE, HOMOLOG OF; COQ7
606980 COENZYME Q8A; COQ8A
607426 COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1
607429 PRENYL DIPHOSPHATE SYNTHASE, SUBUNIT 1; PDSS1
609825 COQ2, S. CEREVISIAE, HOMOLOG OF; COQ2
610564 PRENYL DIPHOSPHATE SYNTHASE, SUBUNIT 2; PDSS2
612016 COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4
612837 COQ9, S. CEREVISIAE, HOMOLOG OF; COQ9
612898 COENZYME Q4, S. CEREVISIAE, HOMOLOG OF; COQ4
614647 COQ6, S. CEREVISIAE, HOMOLOG OF; COQ6
614650 COENZYME Q10 DEFICIENCY, PRIMARY, 6; COQ10D6
614651 COENZYME Q10 DEFICIENCY, PRIMARY, 2; COQ10D2
614652 COENZYME Q10 DEFICIENCY, PRIMARY, 3; COQ10D3
614654 COENZYME Q10 DEFICIENCY, PRIMARY, 5; COQ10D5
615567 COENZYME Q8B; COQ8B
616276 COENZYME Q10 DEFICIENCY, PRIMARY, 7; COQ10D7
616733 COENZYME Q10 DEFICIENCY, PRIMARY, 8; COQ10D8
Molecular Genetic Pathogenesis
The pathogenesis of primary CoQ  deficiency is still not clear and the molecular basis of the
locus heterogeneity of this group of disorders remains to be elucidated. Although the bioenergetic
defect plays a crucial role in the pathophysiology of CoQ  deficiency, CoQ  carries out a
number of fundamental functions in cells (it is a cofactor of other mitochondrial dehydrogenases,
an essential antioxidant, and a modulator of apoptosis), suggesting that other mechanisms are
involved.
In fact, it has been shown in cells that severe CoQ  deficiency causes a marked reduction in ATP
production without increased production of reactive oxygen species (ROS), while mild CoQ
deficiency is associated with high ROS production without significant impairment of cellular
10
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bioenergetics [Quinzii et al 2010].
In addition, CoQ  deficiency impairs de novo pyrimidine synthesis, further contributing to
disease pathogenesis [López-Martín et al 2007].
Note: In this section the genes associated with primary CoQ  deficiency are ordered by gene.
COQ2
Gene structure. COQ2 consists of seven exons [Forsgren et al 2004]. The open reading frame
contains four in-frame ATG initiation codons (termed ATG1-4 [López-Martín et al 2007]); the
third one produces a transcript similar to yeast COQ2. Human COQ2 cDNA originating from
ATG1, ATG2, and ATG3 (but not from ATG4) can complement the defective respiratory
phenotype of yeast COQ2-null strains [Forsgren et al 2004, López-Martín et al 2007, Mollet et al
2007].
Note: The presence of multiple possible initiation codons has generated confusion in naming
COQ2 pathogenic variants. The majority of reports consider the most 5’ ATG (ATG1) as the
initiation codon and the longer transcript NM_015697.7 as reference. GeneReviews adheres to
this nomenclature. However, changes to this convention are possible; it was recently proposed to
transition from legacy nomenclature to nucleotide 1 corresponding to the A of ATG4 [Desbats et
al 2016].
Benign variants. Multiple rare benign COQ2 variants have recently been associated with
sporadic multiple-system atrophy [Mitsui et al 2013]; however, this finding is still under debate
and further confirmation is needed [Mitsui et al 2013, Jeon et al 2014, Schottlaender & Houlden
2014, Sharma et al 2014].
The p.Val393Ala COQ2 variant, which is relatively common in the Japanese population, has not
been found in European or North American populations.
Pathogenic variants. COQ2 was the first gene found to be mutated in individuals with primary
CoQ  deficiency [Quinzii et al 2006]. COQ2 pathogenic variants include mainly missense
alleles; truncating variants have also been reported (Table 3).
To date COQ2 pathogenic variants have been reported in ten families with primary CoQ
deficiency [Quinzii et al 2006, Diomedi-Camassei et al 2007, Mollet et al 2007, Dinwiddie et al
2013, Jakobs et al 2013, McCarthy et al 2013, Mitsui et al 2013, Scalais et al 2013, Desbats et al
2015b, Desbats et al 2016].
Table 3.
Selected Pathogenic COQ2 Variants that Cause Primary CoQ  Deficiency
DNA Nucleotide Change
(Alias )
Predicted Protein Change
(Alias ) Reference Sequences
c.382A>G
(232A>G)
p.Met128Val
(Met78Val)
NM_015697.7
NP_056512.5
c.437G>A p.Ser146Asn
c.545T>G p.Met182Arg
c.590G>A p.Arg197His
c.683A>G p.Asn228Ser
c.890A>G p.Tyr297Cys
c.905C>T p.Ala302Val
c.1159C>T p.Arg387Ter
10
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1.
DNA Nucleotide Change
(Alias )
Predicted Protein Change
(Alias ) Reference Sequences
c.1197delT
(1198delT)
p.Asn401IlefsTer15
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Variant designation that does not conform to current naming conventions
Normal gene product. COQ2 encodes a 421-amino acid
para-hydroxybenzoate:polyprenyltransferase (NP_056512.5) required for the second step of the
final reaction sequence of CoQ biosynthesis. COQ2 catalyzes the condensation of
4-hydroxybenzoate with polyprenyl-pyrophosphate, generating the first membrane-bound CoQ
intermediate [Ashby et al 1992].
The COQ2 enzyme is highly conserved throughout evolution. The human protein contains a
N-terminal mitochondrial leader sequence, two conserved putative substrate-binding domains
(which are rich in aspartic acid residues) and six predicted trans-membrane helices [Forsgren et al
2004].
For information on yeast studies, see Coenzyme Q  Deficiency – Model Organisms, COQ2.
Abnormal gene product. All coenzyme Q  deficiency-related COQ2 pathogenic variants
reported to date act through a loss-of-function mechanism, reducing the polyprenyl-transferase
activity, as proved by the lack of complementation in yeast strains harboring deletion in the
COQ2 ortholog [Mollet et al 2007] or by a reduced incorporation of radiolabeled substrates into
CoQ  [Quinzii et al 2006]. Although genotype-phenotype correlations are still unclear, most
COQ2 pathogenic variants behave as hypomorphic alleles, retaining residual activity that may
contribute to the phenotype.
All known COQ2 pathogenic variants affect highly conserved amino acid residues. The variant
c.890A>G changes a highly conserved tyrosine to cysteine at amino acid 297 within the third
predicted transmembrane domain. Variants p.Ser146Asn and p.Arg197His are located in the
putative substrate-binding site (UbiA), whereas p.Asn228Ser is located in the first putative
transmembrane domain.
COQ4
Gene structure. COQ4 spans a region of about 12 kb and has two transcript variants (details in
Table A, Gene, COQ4). The longer transcript NM_016035.4 has seven exons. An alternate
transcript (NM_001305942.1) is shorter and has four exons.
COQ4 is ubiquitously expressed, with higher levels in liver, lung, and pancreas [Casarin et al
2008].
Pathogenic variants. COQ4 pathogenic variants have been reported in eleven affected
individuals from eight unrelated families [Brea-Calvo et al 2015, Chung et al 2015].
A patient with haploinsufficiency of COQ4 due to a de novo 3.9-Mb deletion of chromosome
9q34 and documented CoQ  deficiency in fibroblasts had encephalomyopathic manifestations
[Salviati et al 2012].
Table 4.
Selected COQ4 Pathogenic Variants that Cause Primary CoQ  Deficiency
1 1
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DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.155T>C p.Leu52Ser
NM_016035.4
NP_057119.2
c.190C>T p.Pro64Ser
c.421C>T p.Arg141Ter
c.433C>G p.Arg145Gly
c.521_523delCCA p.Thr174del
c.718C>T p.Arg240Cys
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Normal gene product. COQ4 transcript NM_016035.4 encodes coq4 isoform 1, which consists
of 265 amino acids, localizes to mitochondria, and is required for CoQ  biosynthesis since it
efficiently restores both growth in glycerol and CoQ content when expressed in a COQ4-null
yeast strain.
An alternate transcript (NM_001305942.1) encodes coq4 isoform 2, which has 100 amino acids
and unknown function; it lacks the first 24 amino acids that specify the predicted mitochondrial
targeting sequence [Casarin et al 2008].
The precise function of ubiquinone biosynthesis protein COQ4 in CoQ  biosynthesis is still
unknown: the protein lacks enzymatic activity but in yeast it is thought to organize proteins
encoded by other genes involved in the synthesis of CoQ  into a multi-enzymatic complex
[Marbois et al 2009].
Abnormal gene product. Missense COQ4 pathogenic variants expressed in yeast failed to
complement a COQ4  yeast strain [Brea-Calvo et al 2015].
COQ6
Gene structure. COQ6 transcript variant 1 has 12 exons.
Among the 18 putative isoforms resulting from alternative splicing, two full-length transcript
variants NM_182476.2 and NM_182480.2 (designated transcript variants 1 and 2, respectively)
were found to be expressed in several tissues including kidney; however, the longer transcript
variant 1 is more abundant than variant 2. The two isoforms differ in the use of alternative exon
1a or 1b and the splicing of exon 3 (absent in isoform b) [Heeringa et al 2011, Doimo et al 2014]
(see details in Table A, Gene, COQ6).
Pathogenic variants. Two homozygous missense pathogenic variants, c.763G>A and
c.1058C>A, and two heterozygous nonsense pathogenic variants, c.1341G>A and c.1383delG,
were found in four different families with steroid-resistant nephrotic syndrome (SRNS) [Heeringa
et al 2011].
Variant c.763G>A was found in one family from northern Lebanon and one from southern
Turkey, suggesting a possible founder effect [Heeringa et al 2011].
Two nonsense pathogenic variants, c.484C>T and c.564G>A, were found as single heterozygous
pathogenic variants in two individuals with cyclosporine A-dependent nephrotic syndrome and
diffuse mesangial sclerosis, respectively [Heeringa et al 2011].
The missense pathogenic variant, c.1235A>G, was found in the heterozygous state in another
individual with SRNS [Doimo et al 2014].
Table 5.
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1.
Selected COQ6 Pathogenic Variants that Cause Primary CoQ  Deficiency
DNA Nucleotide Change
Predicted Protein Change
(Alias ) Reference Sequences
c.484C>T p.Arg162Ter
NM_182476.2
NP_872282.1
c.564G>A p.Trp188Ter
c.763G>A p.Gly255Arg
c.1058C>A p.Ala353Asp
c.1235A>G p.Tyr412Cys
c.1341G>A p.Trp447Ter
c.1383delG
p.Ile462LeufsTer18
(Gln461fsTer478)
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Variant designation that does not conform to current naming conventions
Normal gene product. COQ6 protein is a flavin-dependent monooxygenase involved in CoQ
synthesis [Ozeir et al 2011]. COQ6 transcript variant 1 encodes isoform a (NP_872282.1), a
468-amino acid protein (54 kd) containing a mitochondrial import sequence. Transcript variant 2
encodes isoform b (NP_872286.2), a 443-amino acid protein (51 kd).
The human COQ6 isoform a localizes to mitochondria when overexpressed in several cell lines
including podocytes. Under endogenous conditions it is expressed in glomeruli but not in tubules
and localizes within cellular processes and Golgi apparatus [Heeringa et al 2011].
A pathogenic variant that reduced COQ6 expression (knockdown) in podocytes caused
mitochondrial depolarization and increased the apoptotic rate through the intrinsic pathway,
leading to growth defect. This phenotype was rescued by treating cells with CoQ  [Heeringa et
al 2011].
For information on yeast studies, see Coenzyme Q  Deficiency – Model Organisms, COQ6.
Abnormal gene product. Alleles p.Trp447Ter, p.Gly255Arg, and p.Tyr412Cys did not rescue the
respiratory deficiency of the COQ6-null yeast strain as did the wild-type, and p.Ala353Asp, and
p.Ile462LeufsTer18 [Doimo et al 2014]. However, in vitro experiments suggest that all the alleles,
with the exception of the nonsense allele p.Trp447Ter, are thought to be hypomorphic, because
modeling of the human pathogenic variant on the correspondent yeast amino acid residue did not
completely abolish the respiratory growth of the yeast strain. Finally, the phenotype of yeast
expressing the human pathogenic alleles recovers after addition of vanillic acid or 3,4
dihydroxybenzoic acid [Doimo et al 2014].
The pathogenic variants p.Tyr412Cys and p.Ala353Asp affect an amino acid located at the flavin
adenine dinucleotide (FAD) binding domain and may negatively interfere with COQ6 binding to
FAD. The p.Gly255Arg variant, which affects a residue located in the active site pocket, and the
p.Trp447Ter and p.Ile462LeufsTer18 variants, affecting residues located at the C-terminal tail,
may cause perturbation of the active site [Doimo et al 2014].
COQ7
Gene structure. COQ7 has two transcript variants each comprising six exons. They differ in the
first exon; the longer transcript (NM_016138.4) encodes a 217-amino acid long protein
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(NP_057222.2), whereas the shorter transcript (NM_001190983.1) uses an alternate 5’ exon,
resulting in a downstream AUG start codon with a shorter N-terminus resulting in a 170-amino
acid protein (NP_001177912.1). See Table A, Gene, COQ7 for a detailed summary of gene and
protein information.
Pathogenic variants. A single affected individual born to consanguineous parents has been
reported to date [Freyer et al 2015] harboring a homozygous c.422T>A missense variant. The
patient manifested mild learning disabilities, muscular hypotonia, and hearing and visual
impairment.
Table 6.
Selected COQ7 Pathogenic Variants that Cause Primary CoQ  Deficiency
DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.422T>A p.Val141Glu
NM_016138.4
NP_057222.2
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Normal gene product. COQ7 is a mitochondrial di-iron oxidase responsible for the penultimate
step of CoQ synthesis, hydroxylating 5-demethoxyubiquinol (DMQH2) in the presence of
NADH.
Abnormal gene product. The variant p.Val141Glu likely affects enzymatic function by
impairing iron binding. Of note, supplementation of fibroblasts from the affected individual with
2,4-dihydroxybenzoic acid resulted in increased CoQ  content and restored the combined
activities of Complex I+III and II+III [Freyer et al 2015].
COQ8A
Gene structure. COQ8A (previous symbols: ADCK3, COQ8, CABC1) comprises 15 exons.
Alternatively spliced transcript variants have been found; however, their full-length nature has not
been determined. The gene is ubiquitously expressed, with greater abundance in heart and
skeletal muscle [Iiizumi et al 2002].
Pathogenic variants. COQ8A pathogenic variants causing autosomal recessive ataxia associated
with CoQ deficiency have been described extensively [Lagier-Tourenne et al 2008, Mollet et al
2008, Anheim et al 2010, Gerards et al 2010, Horvath et al 2012, Terracciano et al 2012, Mignot
et al 2013, Blumkin et al 2014, Liu et al 2014, Barca et al 2016, Hikmat et al 2016].
More than 20 pathogenic variants have been reported, including missense, nonsense, and
frameshift variants and a multiexon deletion (from exon 3 to exon 15).
To date all pathogenic variants reported are private and no founder effect has been identified.
Table 7.
Selected COQ8A Pathogenic Variants that Cause Primary CoQ  Deficiency
DNA Nucleotide Change
(Alias ) Predicted Protein Change Reference Sequences
c.637C>T
(636C>T)
p.Arg213Trp
NM_020247.4
NP_064632.2
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1.
2.
3.
4.
5.
DNA Nucleotide Change
(Alias ) Predicted Protein Change Reference Sequences
c.811C>T p.Arg271Cys
c.815G>A p.Gly272Asp
c.815G>T p.Gly272Val
c.895C>T p.Arg299Trp
c.993C>T p.Leu314_Gln360del
c.1042C>T p.Arg348Ter
c.1081-1_1082dupGTA --
c.1136T>A p.Leu379Ter
c.1398+2T>C 
c.1523T>C p.Phe508Ser
c.1541A>G p.Tyr514Cys
c.1645G>A p.Gly549Ser
c.1651G>A
(1655G>A)
p.Glu551Lys
c.1750_1752delACC p.Thr584del
c.1813dupG
(1812_1813insG)
p.Glu605GlyfsTer125
c.1844dupG
(1844_1845insG)
p.Ser616LeufsTer114
c.1844G>A p.Gly615Asp
g.227150977_227195656del44680
See footnote 4
NC_000001.10 
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Variant designation that does not conform to current naming conventions
Causes the skipping of exon 8 leading to an in-frame deletion of 47 amino acids (p.Lys314_Gln360del) [Lagier-
Tourenne et al 2008]
Results in the formation of at least two different abnormal splicing variants [Lagier-Tourenne et al 2008]
Mignot et al [2013]; 29-kb deletion of exons 3 to 15 (hg19)
Genome assembly hg19
Normal gene product. COQ8A encodes a 647-amino acid protein that belongs to the UbiB
protein kinase-like family and contains the conserved kinase motif in the region responsible for
ATP binding and phosphotransfer reaction, but lacks the conserved kinase C-term motif.
Moreover, it presents an N-terminal domain that is absent in the other proteins of the kinase
family and it appears to be specifically related to ubiquinone metabolism [Stefely et al 2015].
In humans there are five paralogs belonging to the aarF domain-containing protein kinase
(ADCK1-5); among them, COQ8A and COQ8B are highly similar and both are involved in
CoQ  biosynthesis [Lagier-Tourenne et al 2008, Ashraf et al 2013]. COQ8A localizes in
mitochondria.
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Computational and in vitro analyses prove that COQ8A forms homodimers after dimerization at
the level of the transmembrane alpha-helices [Khadria et al 2014] and that the kinase motif
displays magnesium (Mg(2+))-dependent ATPase activity [Wheeler & Jia 2015].
For information on yeast studies, see Coenzyme Q  Deficiency – Model Organisms, COQ8A.
Abnormal gene product. The variants p.Arg213Trp, p.Gly272Val, p.Gly272Asp, and
p.Glu551Lys predict changes in highly conserved amino acids of the protein, although none are in
the kinase motifs [Mollet et al 2008].
The p.Tyr514Cys allele affects a residue proximal to the aspartates that bind the magnesium ions
chelated by ATP [Lagier-Tourenne et al 2008].
The 1-bp frameshift insertion c.1813dupG results in the formation of a longer abnormal product
(728 amino acids) and it is thought to modify an important domain of the protein altering the
putative interaction or regulation between COQ8A and COQ9 [Mollet et al 2008].
The homozygous frameshift pathogenic variant p.Ser616LeufsTer114 causes the loss of the stop
codon, leading to a 81-amino acid longer protein. The patient had significant CoQ  deficiency
and reduced mitochondrial respiratory chain enzyme activity.
The two nonsense pathogenic variants p.Arg348Ter and p.Leu379Ter cause a premature stop
codon that triggers nonsense-mediated mRNA decay, leading to complete absence of functional
COQ8A protein. Due to its regulatory role and to the presence of at least another ADCK protein
with similar function (although patients with mutation of COQ8A do not have COQ8B
up-regulation), the complete lack of residual functional protein is compatible with life [Gerards et
al 2010].
The c.1081-1_1082dupGTA pathogenic variant does not alter the splicing of the transcript but
causes insertion of three nucleotides, resulting in a stop codon [Mignot et al 2013].
The p.Phe508Ser variant is localized in one motif of the kinase domain [Mignot et al 2013].
The p.Gly549Ser and p.Gly615Asp pathogenic variants are in the C-terminal domain common to
COQ8A and COQ8B [Lagier-Tourenne et al 2008, Mignot et al 2013].
COQ8B
Gene structure. COQ8B spans 12 kb. Among the hypothetic 17 putative alternative splicing
variants, the longest transcript NM_024876.3 contains 15 exons; exon 1 is non-coding [Ashraf et
al 2013].
Pathogenic variants. Recessive loss-of-function pathogenic variants in COQ8B have been
described in patients with steroid-responsive nephrotic syndrome (SRNS) associated with
primary CoQ  deficiency [Ashraf et al 2013].
Table 8.
Selected COQ8B Pathogenic Variants that Cause Primary CoQ  Deficiency
DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.101G>A p.Trp34Ter
NM_024876.3
NP_079152.3
c.532C>T p.Arg178Trp
c.645delT p.Phe214LeufsTer14
c.857A>G p.Asp286Gly
c.954_956dup p.Thr319dup
c.958C>T p.Arg320Trp
c.1027C>T p.Arg343Trp
10
10
10
10
Primary Coenzyme Q10 Deficiency - GeneReviews® - NCBI B... https://www.ncbi.nlm.nih.gov/books/NBK410087/
20 di 29 15/03/17, 17:31
DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.1199dupA p.His400AsnfsTer11
c.1356_1362delGGGCCCT p.Gln452HisfsTer261
c.1430G>A p.Arg477Gln
c.1447G>T p.Glu483Ter
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Normal gene product. Transcript variant NM_024876.3 encodes isoform a, which is a 60.1-kd
protein that contains a helical domain, an ABC1 domain, and a kinase domain [Ashraf et al
2013]. COQ8B is one of the five ADCK paralogs and is highly similar to COQ8A, a putative
kinase involved in CoQ  biosynthesis [Lagier-Tourenne et al 2008]. It is conserved in several
species and displays high sequence similarity with S. cerevisiae Coq8/Abc1 protein [Ashraf et al
2013].
In humans, COQ8A expression exceeds COQ8B in several tissues with the exception of kidney.
COQ8B is highly expressed in podocyte cell bodies and primary processes and, to a lesser extent,
in renal glomeruli and in proximal tubules and collecting ducts. Analysis of subcellular fractions
from cultured podocytes reveals that COQ8B resides both in mitochondria and cytosol,
suggesting a localized function at ruffles and foot processes of podocytes besides its role in CoQ
biosynthesis [Ashraf et al 2013].
See also Coenzyme Q  Deficiency – Model Organisms, COQ8B.
Abnormal gene product. All the reported missense pathogenic variants affect conserved
residues. Patients have reduced levels of CoQ  in both primary skin fibroblasts and
lymphoblastoid-derived cells.
All individuals with biallelic pathogenic variants in COQ8B have SRNS; however, the phenotype
depends on the genotype [Ashraf et al 2013]:
The patient homozygous for the p.His400AsnfsTer11 truncating variant had the earliest
onset and developmental delay.
The patient homozygous for the p.Arg178Trp amino acid change had diffuse
glomerulosclerosis.
Homozygosity for the p.Gln452HisfsTer261 pathogenic variant was found in two sibs of
Indian ancestry with renal histology and collapsing focal segmental glomerulosclerosis
(cFSGS). Notably, cFSGS is common in individuals with mutation of COQ8B as well as in
the pdss2 kd/kd mouse model [Saiki et al 2008, Ashraf et al 2013].
COQ9
Gene structure. COQ9 has nine exons. No alternative splicing variants are known.
Pathogenic variants. One patient of Pakistani origin with multiple-system disease characterized
by intractable seizures, global developmental delay, hypertrophic cardiomyopathy, and renal
tubular dysfunction was homozygous for the c.730C>T pathogenic variant in exon 7 resulting in a
premature stop codon (p.Arg244Ter) [Duncan et al 2009].
The homozygous loss-of-function variant c.521+1del was reported in a child of Turkish origin
with fatal neonatal lactic acidosis and encephalopathy [Danhauser et al 2016].
Table 9.
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Selected COQ9 Pathogenic Variants that Cause Primary CoQ  Deficiency
DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.521+1delG NM_020312.3
NP_064708.1c.730C>T p.Arg244Ter
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Normal gene product. COQ9 encodes a 318-amino acid protein that is involved in the synthesis
of CoQ  [Duncan et al 2009].
The crystal structure of the human protein reveals that COQ9 is homologous to the TetR family of
transcriptional regulators but does not retain any DNA binding ability. It is organized as a
homodimer and contains a hydrophobic pocket, responsible for binding of lipid molecules (likely
CoQ  or CoQ  precursor) and a binding surface crucial for protein-protein interaction with
Coq7 [Lohman et al 2014].
See also Coenzyme Q  Deficiency – Model Organisms, COQ9.
Abnormal gene product. The c.730C>T pathogenic variant is presumed to cause nonsense-
mediated mRNA decay, as no transcript was detected in patient fibroblasts.
The c.521+1del pathogenic variant affects splicing with the skipping of exons 4 and 5
(p.Ser127_Arg202del), as shown by sequencing of the COQ9 transcript in the patient’s
fibroblasts, with consequent degradation of the truncated protein [Danhauser et al 2016].
See also Coenzyme Q  Deficiency – Model Organisms, COQ9.
PDSS1
Gene structure. PDSS1 spans more than 49.14 kb and comprises 12 exons. There is only one
coding transcript, which is 1,679 bp long.
Pathogenic variants. PDSS1 pathogenic variants have been identified in only two families with
primary CoQ  deficiency to date:
Two sibs with encephalopathy, peripheral neuropathy, optic atrophy, cardiac valvulopathy,
and mild lactic acidosis were homozygous for the c.924T>G missense variant in exon 10
[Mollet et al 2007].
An individual with developmental delay, nephrotic syndrome, and failure to thrive was
compound heterozygous for two novel variants: c.661_662insT and c.1108A>C [Vasta et al
2012].
Table 10.
Selected PDSS1 Pathogenic Variants that Cause Primary CoQ  Deficiency
DNA Nucleotide Change
(Alias ) Predicted Protein Change Reference Sequences
c.661_662insT
(661C>CT)
p.Arg221LeufsTer16
NM_014317.3
NP_055132.2c.924T>G
(977T>G)
p.Asp308Glu
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1.
DNA Nucleotide Change
(Alias ) Predicted Protein Change Reference Sequences
c.1108A>C
(1108A>AC)
p.Ser370Arg
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Variant designation that does not conform to current naming conventions
Normal gene product. PDSS1 encodes decaprenyl-diphosphate synthase subunit 1 (previously
reported as DPS1) which is required for the synthesis of the polyisoprenoid chain of the
appropriate length, the first step in CoQ  biosynthesis. The protein is composed of 415 amino
acids.
It is an ortholog of Schizosaccharomyces pombe Dps1. Unlike in S. cerevisiae where the
ubiquinone side chain is synthesized by the monomeric enzyme COQ1, in S. pombe and in
mammals the PDSS1 polypeptide interacts with the product of PDSS2 forming a heterotetramer
that is responsible for the elongation of the prenyl side chain of CoQ  and determines the
isoprenoid chain length of ubiquinone [Saiki et al 2005].
Abnormal gene product. In the absence of PDSS1, decaprenyl-diphosphate synthase is not
functional and does not produce CoQ .
For information on yeast studies, see Coenzyme Q  Deficiency – Model Organisms, PDSS1.
PDSS2
Gene structure. The gene has at least two different transcript variants that share the first three
exons; only the longest (NM_020381.3), which has eight exons, is believed to encode a
functional subunit of the decaprenyl diphosphate synthase [Saiki et al 2005].
Pathogenic variants. To date PDSS2 pathogenic variants have been reported in two families; the
phenotypes ranged from fatal Leigh syndrome and nephrotic syndrome to infantile-onset
encephalomyopathy with ataxia, deafness, retinitis pigmentosa, and kidney disease [Rötig et al
2000, López-Martín et al 2007, Rahman et al 2012]. The patient reported by López-Martín et al
[2007] was compound heterozygous for two novel variants, c.964C>T and c.1145C>T.
Table 11.
Selected PDSS2 Pathogenic Variants that Cause Primary CoQ  Deficiency
DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.964C>T p.Gln322Ter NM_020381.3
NP_065114.3c.1145C>T p.Ser382Leu
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff
have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.
Normal gene product. The protein product of PDSS2 (previously reported as DLP1) is the
second subunit of decaprenyl diphosphate synthase, which is required for the elongation of the
prenyl side chain of CoQ . The PDSS2 protein consists of 399 amino acids.
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Unlike S. cerevisiae, the prenyl diphosphate synthase in humans acts as a heterotetrameric
complex, formed by two protein subunits encoded by PDSS1 and two protein subunits encoded
by PDSS2 [Saiki et al 2005]. The same heterotetrameric complex is also found in mice and S.
pombe.
Abnormal gene product. In the absence of PDSS2, decaprenyl-diphosphate synthase is not
functional and does not produce CoQ . The PDSS2 pathogenic variants reported by López-
Martín et al [2007] act through a loss-of-function mechanism, as suggested by substrate
incorporation experiments showing a CoQ  biosynthetic defect in fibroblasts from an affected
individual when incubated with radioactive para-hydroxybenzoate (PHB), compared with normal
synthesis in cells incubated with radiolabeled PHB and decaprenyl-PP.
For information on mouse studies, see Coenzyme Q  Deficiency – Model Organisms, PDSS2.
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